Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

17
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
17
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autonomic Dysfunction in Long COVID Is Distinct From Pure Autonomic Failure.

Journal of the American College of Cardiology·2026
Same author

Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure.

Movement disorders : official journal of the Movement Disorder Society·2026
Same authorSame journal

Cardiovascular pharmacology of dopaminergic agents in humans: a review.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Addressing the needs of nano-rare patients: the n-Lorem experience.

Nucleic acids research·2026
Same author

The Parkinsonism of Salvador Dalí.

European neurology·2026
Same author

Long-term outcomes of hyperadrenergic orthostatic hypotension.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026

Related Experiment Video

Updated: Apr 28, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K

Novel therapeutic approaches in multiple system atrophy.

Jose-Alberto Palma1, Horacio Kaufmann

  • 1Department of Neurology, Dysautonomia Center, New York University School of Medicine, 530 First Av, Suite 9Q, New York, NY, 10016, USA.

Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society
|June 15, 2014
PubMed
Summary

Multiple system atrophy (MSA) is a progressive neurodegenerative disease. This review explores potential treatments targeting alpha-synuclein, neuroinflammation, and oxidative stress to halt MSA progression.

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

9.3K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

474

Related Experiment Videos

Last Updated: Apr 28, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

9.3K
Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:45

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

474

Area of Science:

  • Neurodegenerative diseases
  • Neuroscience
  • Pharmacology

Background:

  • Multiple system atrophy (MSA) is a progressive, adult-onset neurodegenerative disease.
  • Characterized by autonomic dysfunction, parkinsonism, and cerebellar or pyramidal signs.
  • Currently, no treatments can halt or reverse MSA progression.

Purpose of the Study:

  • To review potential therapeutic strategies for Multiple System Atrophy (MSA).
  • To explore pharmacologic approaches targeting key pathogenic mechanisms in MSA.
  • To summarize findings from preclinical models of MSA.

Main Methods:

  • Review of existing literature on MSA pathogenesis and therapeutic targets.
  • Analysis of pharmacologic agents tested in cellular and mouse models of MSA.
  • Categorization of treatments based on their proposed mechanisms of action.

Main Results:

  • Several agents show neuroprotective effects in preclinical MSA models.
  • Treatments target alpha-synuclein aggregation, cell-to-cell transmission, oxidative stress, and neuroinflammation.
  • Examples include sertraline, lithium, rifampicin, riluzole, rasagiline, fluoxetine, minocycline, and mesenchymal stem cells.

Conclusions:

  • Multiple therapeutic avenues show promise for halting MSA progression.
  • Targeting specific pathogenic pathways, such as alpha-synuclein and neuroinflammation, is crucial.
  • Further research and clinical trials are needed to validate these strategies for MSA treatment.